Catecholaminergic Polymorphic Ventricular Tachycardia Clinical Trials

20 clinical trials for Catecholaminergic Polymorphic Ventricular Tachycardia across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) — RECRUITING · PHASE1
• A Phase 2 Study of CRD-4730 in CPVT — RECRUITING · PHASE2
• National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry — RECRUITING
• Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias — RECRUITING
• Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) — RECRUITING · PHASE2
• Clinical Cohort Study - TRUST — RECRUITING
• A PHASE 2, DOUBLE-BLIND, REPEAT-DOSE, PLACEBO-CONTROLLED CROSSOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CRD-4730 IN PARTICIPANTS WITH CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA — RECRUITING · PHASE2
• Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank — RECRUITING
• A PHASE 2, DOUBLE-BLIND, REPEAT-DOSE, PLACEBO-CONTROLLED CROSSOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CRD-4730 IN PARTICIPANTS WITH CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA — TERMINATED · PHASE2
• Healthy-related Quality of Life and Physical Activity of Children With Cardiac Malformations — COMPLETED · NA
• A Phase 2a Trial to Investigate Safety, Tolerability and Exploratory Clinical Efficacy of AGP100 in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia — TERMINATED · PHASE2
• Baby Detect : Genomic Newborn Screening — COMPLETED
• A PHASE 1B, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF A SINGLE INTRAVENOUS DOSE OF SGT-501 IN PATIENTS WITH CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA — NOT_YET_RECRUITING · PHASE1
• A PHASE 2A, INVESTIGATOR AND SUBJECT BLINDED, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CRD-4730 IN PARTICIPANTS WITH CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA — OTHER · PHASE2
• A PHASE 2A, INVESTIGATOR AND SUBJECT BLINDED, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CRD-4730 IN PARTICIPANTS WITH CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT) — COMPLETED · PHASE2
• Physical Activity in Children With Inherited Cardiac Diseases — COMPLETED
• Long Term Monitoring for Risk of Sudden Death — COMPLETED
• Atropine in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) — COMPLETED · NA
• PRETREATMENT WITH ATROPINE TO REDUCE EXERCISE-TRIGGERED VENTRICULAR ECTOPY IN PATIENTS WITH CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT) — NOT_YET_RECRUITING
• Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia — COMPLETED · NA

Refine this search